Who is eligible for clinical trial NCT06677060?

Participants must meet protocol criteria for Heart Failure. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06677060 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-30

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin (NCT06677060)

A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent is required for the optional pre-screening period. The pre-screening assessments do not replace the full screening tests at Visit 1. Upon entering the screening period, all consented participants (after signature of screening ICF) will be screened during an up to 14-day screening period. Participants who meet all screening inclusion/exclusion criteria but are not treated with SGLT2i or are treated for less than 4 weeks will enter a run-in period with dapagliflozin 10 mg once daily for at least 4 weeks (and not more than 6 weeks) before randomisation. Site visits will take place at approximately 2-, 4-, 8-, 16-, and 34-weeks following randomisation. Thereafter visits will occur approximately every 4 months. The study closure procedures will be initiated when the predetermined number of the first secondary endpoint events (ie, the composite of hospitalisation for HF or CV death) is predicted to have occurred i.e., the PACD. In case of premature discontinuation of the blinded study intervention, participants will remain in the study. Unless a participant meets the dapagliflozin specific discontinuation criteria, they will continue to receive open label dapagliflozin 10 mg. It is important that the scheduled study visits and data collection continue according to the study protocol.

Who can join: Review the eligibility criteria below.

Location: Research Site — Birmingham, Alabama

Age range: 40 Years

🧪 Interventions in This Study

Baxdrostat and dapagliflozin (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (953 Sites)

Showing the first 25 of 953 sites.

Research Site — Birmingham, Alabama
Research Site — Centreville, Alabama
Research Site — Fairhope, Alabama
Research Site — Huntsville, Alabama
Research Site — Mobile, Alabama
Research Site — Sheffield, Alabama
Research Site — Vestavia Hills, Alabama
Research Site — Anchorage, Alaska
Research Site — Gilbert, Arizona
Research Site — Glendale, Arizona
Research Site — Tempe, Arizona
Research Site — Tucson, Arizona
Research Site — Dublin, California
Research Site — Huntington Beach, California
Research Site — Inglewood, California
Research Site — La Jolla, California
Research Site — Lakewood, California
Research Site — Lincoln, California
Research Site — Loma Linda, California
Research Site — Los Angeles, California
Research Site — Los Angeles, California
Research Site — Sacramento, California
Research Site — San Diego, California
Research Site — San Dimas, California
Research Site — San Francisco, California

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Heart Failure

REDUCE LAP-HFREF TRIAL — New York, New York
Physiological Effects Ketone Ester in Heart — Cleveland, Ohio
DASH Diet in Heart Failure Outpatients — Sacramento, California
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients — Huntsville, Alabama
LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System. — Birmingham, Alabama
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation — Alexander City, Alabama

Explore by condition: All Heart Failure clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗